12:00 AM
Aug 22, 2016
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Kevetrin thioureidobutyronitrile: Additional Phase I data

An open-label, dose-escalation, U.S. Phase I trial in about 48 patients with advanced solid tumors showed that once-weekly 10-750 mg/m 2 IV Kevetrin given for the first 3 weeks of each 4-week cycle met the primary endpoint with no clinically significant adverse effects reported across...

Read the full 203 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >